Please login to the form below

Not currently logged in
Email:
Password:

AiCuris

This page shows the latest AiCuris news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The treatment - which MSD acquired from German biotech AiCuris - has already been approved for use in the same disease indication for the US last year.

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The $142m upfront payment representing approximately 25 per cent of the consideration is certainly attractive for AiCuris and probably reflects the fact that this drug is for an orphan indication. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    TiGenix appoints Dr Marie Paule Richard. She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... An immunologist with over 25 years of experience in the global biopharmaceutical industry, Richard has previously

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics